Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Key Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Participants \>= 21 years old at time of informed consent. Both men and women and members of all races and ethnic groups will be included * Participants, both men and women, must agree to use an adequate method of contraception prior to study entry, for the duration of study participation, and for 4 months after completion of study * Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to start of study drug administration * Patients must have a histologically or cytologically-confirmed metastatic solid tumor or hematological malignancy that has progressed as follows: * Patients with a solid tumor must have metastatic disease and have progressed on at least 1 line of established therapy that is known to provide clinical benefit, or for whom no standard curative therapy exists. Participants with newly diagnosed, unresectable, locally-advanced or metastatic pancreatic adenocarcinoma and are beginning first-line treatment with a course of chemotherapy are eligible OR * Participants must have a hematological malignancy that is advanced, relapsed, or refractory to at least 1 line of established therapy that is known to provide clinical for the treatment of their disease. Hematological disease included in this study are as follows: * Acute myelogenous leukemia (AML), or * Myelodysplastic syndrome (MDS), o…